| Project/Area Number |
15K09227
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tohoku Medical and Pharmaceutical University |
|---|
Principal Investigator |
EBINA Masahito 東北医科薬科大学, 医学部, 教授 (10280885)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
|
|---|
| Keywords | 肺線維症 / 循環miRNAs / IPF / f-NSIP / PPFE / 難治性 / 治療戦略 / 進行性肺線維症 / 循環miRNA / NSIP / 末梢血中循環miRNA / 線維化病態 / 臨床検体 / 特発性肺線維症 |
|---|
| Outline of Final Research Achievements |
Idiopathic pulmonary fibrosis (IPF), fibrotic non-specific interstitial pneumonia (f-NSIP), and pulmonary parenchymal fibro-elastosis (PPFE) are notorious progressive diseases of pulmonary fibrosis, because of their high intractability. To find out and construct effective treatment strategy against these progressive fibrosis of the lung, we measured and analyzed the circulating miRNA of the patients before and after treatment with medication by anti-pulmonary fibrosis, Nintedanib, Pirfenidone, Tacrolimus, and/or Steroids. These results were compared with our previous results of alteration of circulating miRNAs in the animal models, bleomycin-induced lung fibrosis.
|
